The Pharma Industry Forum on

Medicare Modernization

Understanding and Implementing The Medicare Prescription Drug, Improvement, and Modernization Act of 2003

Monday, April 19, 2004

About

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ("Medicare Modernization Act" or "MMA") makes the most sweeping changes to Medicare since its inception. All pharmaceutical counsel, in order to effectively advise clients, must have a sophisticated understanding of the MMA - with special emphasis on the areas that will most effect pharmaceutical manufacturers.

American Conference Institute has developed this publication for in-house pharma counsel and their outside advisers to provide them with the information they need to understand the MMA and implement and comply with its many provisions.

This publication brought together an experienced faculty of leading national pharmaceutical defense experts, and representatives from CMS and the legislators who fashioned the bill, to provide you with the most practical, timely and sophisticated analysis of the MMA and its implications.

The publication will address critical issues including:

  • The prescription drug discount card
  • Strategies for contracting with PBMs
  • The Medicare drug benefit
  • Effect of the MMA on Medicaid
  • How HSAs will impact drug prices
  • Effective and compliant medication therapy management

Contents & Contributors

About

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ("Medicare Modernization Act" or "MMA") makes the most sweeping changes to Medicare since its inception. All pharmaceutical counsel, in order to effectively advise clients, must have a sophisticated understanding of the MMA - with special emphasis on the areas that will most effect pharmaceutical manufacturers.

American Conference Institute has developed this publication for in-house pharma counsel and their outside advisers to provide them with the information they need to understand the MMA and implement and comply with its many provisions.

This publication brought together an experienced faculty of leading national pharmaceutical defense experts, and representatives from CMS and the legislators who fashioned the bill, to provide you with the most practical, timely and sophisticated analysis of the MMA and its implications.

The publication will address critical issues including:

  • The prescription drug discount card
  • Strategies for contracting with PBMs
  • The Medicare drug benefit
  • Effect of the MMA on Medicaid
  • How HSAs will impact drug prices
  • Effective and compliant medication therapy management

Contents & Contributors

THE IMPACT OF THE PRESCRIPTION DRUG DISCOUNT CARD ON DRUG MANUFACTURERS: OVERVIEW OF REGULATORY REQUIREMENTS FOR MEDICARE DRUG DISCOUNT CARD SPONSORS
Jeffrey G. Micklos, Foley & Lardner LLP

THE PHARMA INDUSTRY FORUM ON MEDICARE MODERNIZATION
Ann Leopold Kaplan, Epstein Becker & Green, P.C.
Wendy C. Goldstein, Epstein Becker & Green, P.C.

THE MEDICARE MODERNIZATION ACT OF 2003: THE INCREASINGLY COMPLEX RELATIONSHIP BETWEEN PBMS, INSURERS AND MANUFACTURERS
Patrick Morrisey, Sidley Austin Brown & Wood LLP

THE MEDICARE MODERNIZATION ACT: A DEFENSE OF PHARMACY BENEFIT MANAGERS?
A. Jeff Ifrah, Paul Hastings Janofsky and Walker
Tara A. Sidney, Paul Hastings Janofsky and Walker

UNDERSTANDING THE INCREASED ROLE OF PBMS IN THE DRUG BENEFIT
Missy Jenkins, Pharmaceutical Care Management Association

MEDICARE MODERNIZATION: MEDICATION THERAPY MANAGEMENT
Sheree R. Kanner, Hogan & Hartson, LLP

AFFIRMATIVE CIVIL ENFORCEMENT AND HEALTH CARE FRAUD
Stuart A. Minkowitz, District of New Jersey

MEDICARE PAYMENT FOR DRUGS IN THE HOSPITAL OUTPATIENT DEPARTMENT
Gordon B. Schatz, Reed Smith

FROM AWP TO ASP MOVING FROM TRANSITION FROM TOO LITTLE INFORMATION TO TOO MUCH? IS THE ENFORCEMENT ENVIRONMENT GOING TO CHANGE FOR THE INDUSTRY?
Carolyn J. McElroy, Mintz Levin Cohn Ferris Glovsky & Popeo, P.C.

THE MOVEMENT OF OIG INTO PRICING: WHAT DOES IT MEAN FOR COMPLIANCE AND IMPLEMENTATION?
William Sarraille, Sidley Austin Brown & Wood LLP
Karen Owen Dunlop, Sidley Austin Brown & Wood, LLP

LIKELY IMPLICATIONS OF THE MMA FOR STATE BUDGETS AND POLICYMAKING
Stephen A. Warnke, Ropes & Gray

UNDERSTANDING THE MEDICARE BENEFICIARY PERSPECTIVE: COST COMPLEXITY CHANGE
John Rother, AARP

MEDICARE REFORM AND THE FUTURE OF EMPLOYER-BASED RETIREE MEDICAL BENEFITS
Alden J. Bianchi, Mintz Levin Cohn Ferris Glovsky & Popeo, P.C.



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0